Acute over-additive natriuretic effects by a combination of finerenone and SGLT2 inhibition in rats with an activated renin-angiotensin-aldosterone system: a mechanistic basis for clinical outcomes?
Event: ESC Congress 2023
Topic: Aldosterone Antagonists
Session: Improving outcomes in heart failure: bench to bedside
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
Event: ESC Congress 2021 - The Digital Experience
Topic: Target Organ Damage/Left Ventricular Hypertrophy
Session: Recent advances in diagnosis/treatment of hypertension
Get the right balance: a novel vasopressin receptor antagonist equally blocks human V1a and V2 receptors and inhibits the release of plasminogen activator inhibitor-1 from cardiomyocytes
Event: ESC Congress 2016
Topic: Pharmacologic therapy
Session: Novel pharmacological therapy in chronic heart failure
